Scholars@Duke
Michael R Abern

Michael R Abern

Associate Professor of Urology
Urology
michael.abern@duke.edu
200 Trent Drive, DUMC Box 2804, Durham, NC 27710
40 Duke Medicine Circle, DUMC Box 3707, Durham, NC 27710

Scholarly Works - Conferences

Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial.

Conference Journal of Clinical Oncology · February 1, 2024 262Background: Stockholm3 is a multiparametric blood test incorporating germline risk, proteins and clinical data which improves prostate cancer (PC) risk stratification compared to PSA, however no validation exists in an ethnically diverse population. Met ... Full text Cite

MANAGEMENT OF COLOVESICAL FISTULAS - IS THERE A COMMON PRACTICE?

Conference DISEASES OF THE COLON & RECTUM · May 2021 Link to item Cite

Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big Ten Cancer Research Consortium BTCRC GU16-043.

Conference Journal of Clinical Oncology · February 20, 2021 328 Background: Anti-PD1/PDL1 immune checkpoint inhibition (CPI) is active in advanced clear cell RCC, but not all patients benefit. Preclinical studies with the combination of hypomethylating agents and CPI resulted in reversal ... Full text Cite

Abstract A066: Performance of the prostate health index (PHI) assay in black men

Conference Cancer Epidemiology, Biomarkers & Prevention · June 1, 2020 AbstractIntroduction: The low specificity of PSA in prostate cancer (PCa) screening has caused excessive biopsies and PCa over-detection. PHI is more specific for clinically significant (cs) PCa (i.e. Gleaso ... Full text Cite

Abstract A082: ENACT: A randomized trial assessing the impact of the Oncotype DX Prostate Cancer Assay on treatment decision in a racially diverse population of men eligible for active surveillance

Conference Cancer Epidemiology, Biomarkers & Prevention · June 1, 2020 AbstractThe Oncotype DX Prostate Cancer Assay® (ODX), a 17-gene expression profile performed on biopsy tissue, has been validated for prediction of adverse pathology at surgery and 10-year risk of metastasis ... Full text Cite

MP75-17 ETHNIC VARIATION IN PROSTATE CANCER DETECTION

Conference The Journal of Urology · April 2020 Full text Cite

Agent Orange and long-term outcomes after radical prostatectomy.

Conference Urol Oncol · July 2015 PURPOSE: To investigate the association between Agent Orange (AO) exposure and long-term prostate cancer (PC) outcomes. MATERIAL AND METHODS: Data from 1,882 men undergoing radical prostatectomy for PC between 1988 and 2011 at Veterans Affairs Health Care ... Full text Link to item Cite

CYSTIC NEPHROMA: A BENIGN TUMOR OR HAMARTOMATOUS PROLIFERATION?

Conference JOURNAL OF INVESTIGATIVE MEDICINE · April 2014 Link to item Cite

EFFECTS OF SODIUM AND FRUCTOSE INTAKE ON PEDIATRIC STONE FORMATION

Conference JOURNAL OF ENDOUROLOGY · September 1, 2012 Link to item Cite

Abstract 5631: The effect of pomegranate extract dose on prostate cancer growth in a carbohydrate restricted mouse xenograft model

Conference Cancer Research · April 15, 2012 AbstractIntroduction: Preclinical studies have shown that dietary carbohydrate restriction slows prostate tumor growth in multiple xenograft models in part due to a reduction insulin-like growth factor (IGF) ... Full text Cite

Abstract 5255: Methionine restriction limits prostate tumor cell proliferation

Conference Cancer Research · April 15, 2012 AbstractIntroduction: Methionine restriction has been shown to have growth inhibitory effects in a number of tumor cell lines in vitro. Methionine restriction has previously been demonstrated to slow PC-3 pr ... Full text Cite